Use of Brain Natriuretic Peptide and Bioimpedance to Guide Therapy in Heart Failure Patients

2010 ◽  
pp. 209-216 ◽  
Author(s):  
Roberto Valle ◽  
Nadia Aspromonte
Keyword(s):  
Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Heart Failure Patients

scholarly journals Association between psychological measures and brain natriuretic peptide in heart failure patients

2012 ◽  
Vol 46 (3) ◽  
pp. 154-162 ◽  
Author(s):  
Corline Brouwers ◽  
Helle Spindler ◽  
Mogens Lytken Larsen ◽  
Hans Eiskær ◽  
Lars Videbæk ◽  
...  
Keyword(s):  
Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Psychological Measures ◽  
Heart Failure Patients

scholarly journals Brain Natriuretic Peptide Levels and Response to Cardiac Resynchronization Therapy in Heart Failure Patients

2006 ◽  
Vol 12 (5) ◽  
pp. 250-253 ◽  
Author(s):  
Reynolds M. Delgado ◽  
Nanthini Palanichamy ◽  
Rajko Radovancevic ◽  
Bojan Vrtotec ◽  
Branislav Radovancevic
Keyword(s):  
Heart Failure ◽  
Cardiac Resynchronization Therapy ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Cardiac Resynchronization ◽  
Resynchronization Therapy ◽  
Heart Failure Patients

scholarly journals Diagnostic, Prognostic, and Therapeutic Value of Circulating miRNAs in Heart Failure Patients Associated with Oxidative Stress

2016 ◽  
Vol 2016 ◽  
pp. 1-13 ◽  
Author(s):  
Md Sayed Ali Sheikh ◽  
Umme Salma ◽  
Baohai Zhang ◽  
Jimei Chen ◽  
Jian Zhuang ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Clinical Management ◽  
Treatment Strategies ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Circulating Mirnas ◽  
Heart Failure Patients

Heart failure is a major public health problem especially in the aging population (≥65 years old), affecting nearly 5 million Americans and 15 million European people. Effective management of heart failure (HF) depends on a correct and rapid diagnosis. Presently, BNP (brain natriuretic peptide) or N-terminal pro-brain natriuretic peptide (NT-proBNP) assay is generally accepted by the international community for diagnostic evaluation and risk stratification of patients with HF. However, regardless of its widespread clinical use, BNP is still encumbered by reduced specificity. As a result, diagnosis of heart failure remains challenging. Although significant improvement happened in the clinical management of HF over the last 2 decades, traditional treatments are ultimately ineffective in many patients who progress to advanced HF. Therefore, a novel diagnostic, prognostic biomarker and new therapeutic approach are required for clinical management of HF patients. Circulating miRNAs seem to be the right choice for novel noninvasive biomarkers as well as new treatment strategies for HF. In this review, we briefly discuss the diagnostic, prognostic, and therapeutic role of circulating miRNAs in heart failure patients. We also mentioned our own technique of extraction of RNA and detection of circulating miRNAs from human plasma and oxidative stress associated miRNAs with HF.

Sign in / Sign up

Export Citation Format

Share Document